Ionis Pharmaceuticals Inc (Ionis), formerly ISIS Pharmaceuticals, Inc., focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.
Headquarters
United States of America
Address
2855 Gazelle Ct, Carlsbad, California, 92010-6670
Website
www.ionispharma.com
Telephone
1 760 9319200
No of Employees
660
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IONS (NASD)
Revenue (2021)
$810.5M
11.1%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
93.6%
(2021 vs 2020)
Market Cap*
$5.4B
Net Profit Margin (2021)
XXX
94.2%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| Nusinersen - Spinal Muscular Atrophy | Spinraza |
| Inotersen - Polyneuropathy | Tegsedi |
| Volanesorsen - Familial Chylomicronemia Syndrome | Waylivra |
| XXX | |
| XXX | |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Official Trials/Tests | In June, the company and AstraZeneca's eplontersen meets endpoints in Phase III ATTRv-PN trial. |
| 2022 | Regulatory Approval | In January, the company announced U.S. Food and Drug Administration (FDA) granted orphan drug designation to eplontersen. |
| 2022 | Others | In January, the company announced Biogen to obtain licence for Ionis’ investigational investigational antisense oligonucleotide (ASO), BIIB115/ION306. |
Competitor Comparison
| Key Parameters | Ionis Pharmaceuticals Inc | Alnylam Pharmaceuticals Inc | Intercept Pharmaceuticals Inc | Arrowhead Pharmaceuticals Inc | Enzo Biochem Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Carlsbad | Cambridge | Morristown | Pasadena | Farmingdale |
| State/Province | California | Massachusetts | New Jersey | California | New York |
| No. of Employees | 660 | 1,665 | 437 | 329 | 451 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joseph Loscalzo, M.D., Ph.D. | Chairman | Executive Board | 2021 | 70 |
| Brett P. Monia, Ph.D. | Chief Executive Officer; Director | Executive Board | 2020 | 60 |
| Elizabeth L. Hougen | Chief Financial Officer; Executive Vice President - Finance | Senior Management | 2013 | 60 |
| Patrick R. O’Neil | General Counsel; Secretary; Chief Legal Officer | Senior Management | 2021 | 48 |
| C. Frank Bennett, Ph.D. | Chief Scientific Officer; Executive Vice President | Senior Management | 2020 | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer